A single rule change can look completely different depending on where you stand. A new prior-authorization deadline is relief to a patient, a workflow change to a provider's biller, and a systems project to a health plan. For each change below, we explain what it is and then break down the impact by audience.
First, the kinds of "changes" you'll hear about
Not every change carries the same weight or moves at the same speed. It helps to know which kind you're looking at:
| Type | Who makes it | What it is |
|---|---|---|
| Legislation (statute) | Congress (or a state legislature) | A law. Sets the big framework and can create or end whole programs and benefits. Often directs agencies to write the detailed rules. |
| Regulation (rule) | Federal or state agencies (e.g., CMS) | The detailed rules that carry out a law. Go through a proposed rule → public comment → final rule cycle and are published in the Federal Register. |
| Sub-regulatory guidance | Agencies (CMS memos, manuals, FAQs) | Instructions that interpret the rules. Faster to issue and change than formal regulations. |
| Annual updates | CMS, states, plans | Yearly adjustments — premiums, thresholds, the drug-plan structure, plan benefits, and rate announcements. Predictable timing, changing numbers. |
The How Programs Are Governed page explains the rulemaking cycle in more depth. Below are the substantive changes worth understanding right now.
Part D deductible limit and yearly drug-cost cap will both rise in 2027
Medicare drug plans (Part D) have a yearly limit on what you pay out of pocket for covered drugs. They also have a top limit on the deductible (the amount you pay before the plan starts to pay). Medicare.gov now lists both figures for 2027. No drug plan may have a deductible above $700 in 2027, up from $615 in 2026. The out-of-pocket cap is $2,400 in 2027, up from $2,100 in 2026. These are limits, and some plans charge less or have no deductible. The 2026 figures apply until the year ends. See the official Medicare.gov Part D costs page, and our 2027 Medicare costs page.
| Audience | Impact |
|---|---|
| Members & caregivers | Your 2027 drug costs may be higher than in 2026, especially if you take costly drugs. Your plan's Annual Notice of Change shows its own deductible and costs. Extra Help payments count toward the cap. |
| Providers & billing | Patients may reach the cap later in the year than before. Expect more questions at the pharmacy counter and in the office about drug costs in early 2027. |
| Brokers & advisors | Both limits change at renewal, so clients' drug-cost comparisons from 2026 will not carry over. Use each plan's own 2027 figures. |
| Case managers & navigators | Clients with ongoing drug needs may face higher costs early in 2027. Check whether they qualify for Extra Help or a Medicare Prescription Payment Plan (a way to spread drug costs over the year). |
| Health-plan operations | Benefit designs, bid materials, and member notices must reflect the new 2027 limits. Systems that track out-of-pocket spending need the new cap. |
A new test could lower coinsurance on some Part B drugs in Original Medicare (GLOBE Model, 2027)
Medicare Part B covers drugs given in a doctor's office or hospital outpatient department, such as many cancer treatments. A 2022 law already requires drug makers to pay Medicare a rebate (a payback) when they raise prices faster than inflation. In a final rule published in October 2026, CMS created a new mandatory test of a different way to figure that rebate. It is called the GLOBE Model (Global Benchmark for Efficient Drug Pricing). The rule takes effect November 30, 2026. Drug makers whose drugs are included must take part. For those drugs, the rebate is compared with a benchmark built from drug prices in a set of other countries. The test covers only some single-source Part B drugs. Drugs for rare diseases, gene and cell therapies, plasma-derived products, and drugs with a negotiated Medicare price are left out. The test runs for five years, starting in April 2027. It applies only to people in Original Medicare, living in randomly chosen ZIP codes, whom CMS selects. It does not apply to Medicare Advantage members. If you are in the test and get an included drug, your coinsurance (your share of the cost) can be lower than usual, and CMS says it will not be higher. You do not apply, and you cannot choose to join or leave. Read the official text in the Federal Register. For how Part B cost sharing works in general, see Understanding Your Costs.
| Audience | Impact |
|---|---|
| Members & caregivers | Most people will see no change. If you are in Original Medicare, live in a selected area, and get an included Part B drug, your coinsurance for that drug may be lower starting in April 2027. Your coverage and your choice of doctor stay the same. Medicare Advantage members are not part of the test. |
| Providers & billing | Providers are not participants. They keep buying and billing these drugs as usual. For selected patients, they charge the reduced coinsurance, and Medicare's share of the payment is adjusted upward to make up the difference. Billing and patient-communication workflows will need to handle this. |
| Brokers & advisors | No effect on plan choice or enrollment rules. It only applies to Original Medicare, so it is useful background for clients who ask how Part B drug costs work. |
| Case managers & navigators | Clients on costly Part B drugs, such as cancer treatments, may see different coinsurance depending on where they live. Selection is by area and is decided by CMS, so check the actual amount owed rather than assuming. |
| Health-plan operations | Medicare Advantage plans are outside the test. Supplemental plans that pay Part B coinsurance (such as Medigap) may see different coinsurance amounts on claims for selected patients, so watch how claims are coordinated. |
Medicaid expansion adults will renew twice a year instead of once (starting January 2027)
If you have Medicaid as an adult through the Affordable Care Act expansion — roughly, adults under 65 who qualify by income alone, not through a disability, pregnancy, or another category — your renewal schedule is about to double. A 2025 law (Public Law 119-21, widely called the One Big Beautiful Bill Act; Section 71107) requires every state and the District of Columbia to re-check eligibility for this group every 6 months instead of every 12, beginning with renewals scheduled on or after January 1, 2027. CMS spelled out the details in a March 2026 State Medicaid Director letter. The 12-month schedule still applies to everyone else: children, pregnant women, people who qualify through disability or age, other income-based groups, and certain American Indians and Alaska Natives (who are exempt even within the expansion group). Twice as many renewals means twice as many chances to lose coverage by missing a notice — even if you still qualify. Keep your address current with your state Medicaid agency, and see Medicaid Eligibility for how renewals work.
| Audience | Impact |
|---|---|
| Members & caregivers | If you're in the expansion group, expect renewal paperwork twice a year starting in 2027. Update your address and phone with the state now, open every letter from Medicaid, and respond by the deadline — most coverage losses in past renewal waves were for missed paperwork, not lost eligibility. |
| Providers & billing | Expect more coverage churn in the expansion population: more patients arriving with lapsed coverage, more retroactive-eligibility and reinstatement work, and more eligibility checks at the front desk. |
| Brokers & advisors | Clients who lose Medicaid at a 6-month check may qualify for a Marketplace Special Enrollment Period. Losing Medicaid mid-year becomes a much more common trigger event to plan for. |
| Case managers & navigators | Renewal support becomes a twice-a-year touchpoint for expansion adults. Flag members with unstable housing or mail access early — they're most at risk of procedural termination. |
| Health-plan operations | Medicaid managed-care plans should expect enrollment volatility in the expansion group from 2027: higher churn, more retroactive terminations and reinstatements, and heavier renewal-outreach workloads alongside the state. |
Medicaid and CHIP will stop paying for gender-transition treatments for minors (October 2026)
In a final rule published in August 2026, CMS barred Medicaid and the Children's Health Insurance Program (CHIP) from paying for medical treatments meant to change a child's body to match a gender identity different from the child's sex. The rule's term for these is "sex-rejecting procedures," and it covers both drugs (such as puberty blockers and cross-sex hormones) and surgeries. Starting October 13, 2026, state Medicaid programs may not pay for these treatments for children under 18, and no federal Medicaid money can be used for them. Separate CHIP programs face the same limits for children under 19. The rule does not apply to care for a medically verifiable disorder of sexual development, to the same drugs or procedures when used for other medical reasons, or to treatment of complications from past procedures. For children already on hormone therapy when the rule takes effect, federal funding can continue for a tapering-off period of up to 6 months. Read the official text in the Federal Register, and check with your state Medicaid agency for how your state is carrying it out.
| Audience | Impact |
|---|---|
| Members & caregivers | If your child gets these treatments through Medicaid or CHIP, talk with your child's doctor and your state Medicaid agency before October 13, 2026 — especially about the limited tapering period for hormone therapy already underway. Your child's other health care is not affected by this rule. |
| Providers & billing | After the effective date, these treatments for patients under the age limits are no longer payable under Medicaid or separate CHIP. The exceptions — disorders of sexual development, other medical uses of the same drugs or procedures, and treating complications — make precise documentation and coding essential. |
| Brokers & advisors | Little direct sales impact, but families asking about coverage for this care should be referred to their state agency and the treating clinicians rather than advised — coverage outside Medicaid/CHIP varies by state and plan. |
| Case managers & navigators | Identify affected families early. Children currently on hormone therapy have a limited transition window, so timely conversations with the care team and the state agency matter most. |
| Health-plan operations | Medicaid and CHIP managed-care plans must update benefit configuration, claims edits, and prior-authorization logic by the effective date, apply the rule's exceptions correctly, and administer the 6-month hormone-therapy tapering period. |
Hospice: everyone will now get a written list of what hospice won't cover (August 2026)
When you choose hospice care under Medicare, you sign an "election statement" — the form that starts the benefit. Since 2020, you could also ask the hospice for an addendum: a written list of the items, services, and drugs the hospice has decided are unrelated to your terminal illness, and so won't be paid for as part of hospice care. Until now, the hospice only had to give you that list if you asked. In a final rule published in August 2026, CMS made the addendum automatic. Starting October 1, 2026, hospices must give it to every Medicare patient at the time they elect hospice. The same rule also allows more of the hospice's physicians — not only the medical director — to handle a discharge from hospice, and it extends the option to do the required recertification "face-to-face" visit by telehealth through the end of 2027, with new billing-code requirements for those visits. Read the official text in the Federal Register, and see our hospice and home health guide for how the benefit works.
| Audience | Impact |
|---|---|
| Members & caregivers | You no longer have to know to ask. Every new hospice patient gets a clear, written list of what the hospice considers unrelated to the terminal illness — which helps you spot coverage gaps early and question anything that seems wrong. See Hospice & Home Health. |
| Providers & billing | Hospices must prepare and deliver the addendum for every election, not just on request — a real documentation and intake-workflow change. Discharge sign-off gains flexibility (a physician member or designee of the interdisciplinary group can now discharge, not only the medical director), and telehealth face-to-face recertification visits continue through 2027 but need the new codes or modifiers. |
| Brokers & advisors | Hospice is paid under Original Medicare even for Medicare Advantage members, so this applies regardless of plan type. Useful context when clients ask what hospice does and doesn't cover. |
| Case managers & navigators | The addendum becomes a standard document you can review with every hospice family — a concrete starting point when a needed drug or service is labeled "unrelated" and the family wants to understand or challenge that call. |
| Health-plan operations | Expect fewer surprises in coordinating non-hospice claims for members who elect hospice, since the "unrelated to terminal illness" determinations are now documented up front for everyone. |
Proposed limits on the "provider taxes" states use to fund Medicaid (July 2026)
Many states pay part of their Medicaid share with taxes on health care providers, such as hospitals and nursing homes (often called "provider taxes"). Federal rules already cap how much states can raise this way. A 2025 federal law tightened those caps. In July 2026, CMS published a proposed rule (a draft regulation open for public comment) to carry that law out. In short, each state's allowed tax level would be frozen at its mid-2025 level. States that expanded Medicaid would then see their allowed level step down over time, starting in late 2027. This money helps fund state Medicaid programs, so tighter limits could squeeze state budgets. This is still a proposal — details can change before a final rule. Read the official text in the Federal Register.
| Audience | Impact |
|---|---|
| Members & caregivers | No direct change to your benefits or eligibility right now. Over time, tighter state funding can pressure states to trim optional benefits or provider payments — worth watching through your state Medicaid agency. |
| Providers & billing | Hospitals, nursing homes, and other taxed provider classes are directly affected. State financing changes often ripple into supplemental and directed payments — watch your state's response and the comment period. |
| Brokers & advisors | Little direct effect on plan sales, but state Medicaid budget pressure can shift eligibility processing and program stability for dual-eligible and Medicaid clients. |
| Case managers & navigators | No immediate eligibility change. If state budgets tighten later, expect possible changes to optional benefits and waiver programs — stay alert to state announcements. |
| Health-plan operations | Medicaid managed-care plans should watch closely: state financing changes can flow into capitation rates and state-directed payment arrangements. Track rulemaking and each state's plan. |
Medicare drug-cost changes (Inflation Reduction Act)
A 2022 federal law made the largest set of changes to Medicare prescription drug coverage (Part D) in years. The provisions phase in over several years. In broad strokes:
- A yearly cap on what you pay for Part D drugs. Once your out-of-pocket drug spending hits an annual maximum, the plan covers the rest for the year. This replaced the old open-ended "catastrophic" coinsurance. The cap amount is set in law and adjusted each year — check the current figure on Medicare.gov.
- Insulin capped at $35 a month for covered insulin under Medicare. See Medicare diabetes coverage for how the cap works.
- Recommended adult vaccines at no cost under Part D.
- Medicare drug price negotiation. For the first time, Medicare negotiates prices for selected high-cost drugs, with negotiated prices phasing in.
- Inflation rebates. Drug makers owe rebates to Medicare if they raise certain prices faster than inflation.
- Expanded "Extra Help." More people with limited income qualify for full help paying for Part D.
| Audience | Impact |
|---|---|
| Members & caregivers | More predictable drug costs and a firm yearly ceiling; insulin and many vaccines cost less. Worth re-checking your plan each year during open enrollment, since the drug-benefit structure changed. See Understanding Your Costs and Getting Help Paying. |
| Providers & billing | Fewer patients abandoning prescriptions over cost; formulary and coverage questions may shift as negotiated prices and formularies adjust. |
| Brokers & advisors | Plan comparisons change meaningfully year to year; clients need help re-evaluating Part D and Medicare Advantage drug coverage at renewal. |
| Case managers & navigators | More clients likely qualify for expanded Extra Help — screen for it. The out-of-pocket cap eases a common crisis point for high-drug-cost clients. |
| Health-plan operations | Redesigned Part D benefit phases, new liability arrangements, and negotiated-price handling — significant benefit-configuration and systems work. |
Protection from surprise medical bills (No Surprises Act)
This federal law protects people from many "surprise" out-of-network bills — for example, emergency care, or care from an out-of-network clinician at an in-network facility (like an anesthesiologist you didn't choose). In those situations you generally can't be balance-billed beyond your normal in-network cost sharing. It also gives people who are uninsured or paying cash the right to a Good Faith Estimate of costs in advance, and sets up an independent dispute-resolution process between providers and plans over the payment amount.
| Audience | Impact |
|---|---|
| Members & caregivers | Strong protection from shock bills in emergencies and at in-network facilities. If you get a surprise bill anyway, you can dispute it — see Your Rights & Protections. |
| Providers & billing | New notice-and-consent rules, Good Faith Estimate obligations, and a payment dispute (IDR) process to learn and staff for. |
| Brokers & advisors | A consumer protection worth explaining; reduces a common fear about network gaps. |
| Case managers & navigators | A concrete tool when a client is hit with an out-of-network or surprise bill; know the dispute path. |
| Health-plan operations | Claims handling, disclosures, and dispute-resolution participation all change; coordination with provider contracting. |
Medicaid "unwinding" — renewals resumed
During the COVID-19 emergency, states were required to keep most people continuously enrolled in Medicaid without the usual renewals. That requirement ended, and states resumed regular eligibility checks ("redeterminations"). Everyone on Medicaid must be re-evaluated, and people who don't respond to a renewal notice — or who no longer qualify — can lose coverage even if they're still eligible. Many who lose Medicaid can move to other coverage, such as a Marketplace plan or employer coverage.
| Audience | Impact |
|---|---|
| Members & caregivers | You must actively renew; don't ignore state mail. If you lose Medicaid, you may qualify for a Marketplace plan with subsidies — a coverage loss opens a Special Enrollment Period (see Enrollment & Deadlines). |
| Providers & billing | Re-verify Medicaid eligibility at each visit; coverage can lapse between appointments. Expect more self-pay and coverage-transition situations. |
| Brokers & advisors | People losing Medicaid are a major Marketplace Special-Enrollment population needing help transitioning. |
| Case managers & navigators | Front-line work: help clients complete renewals, update contact info, and transition to other coverage to prevent gaps. |
| Health-plan operations | Large membership swings, redetermination outreach, and enrollment/dis-enrollment processing at scale. |
Faster, clearer prior authorization (CMS Interoperability & Prior Authorization Rule)
A federal regulation requires many health plans — Medicare Advantage, Medicaid, CHIP, and Marketplace plans — to make prior authorization faster and more transparent. Broadly, affected plans must decide requests within set timeframes (with a faster clock for urgent requests), give a specific reason when they deny, publicly report prior-authorization data, and build electronic systems (APIs) so providers can submit and track requests digitally. The requirements phase in over time.
| Audience | Impact |
|---|---|
| Members & caregivers | Faster decisions and clearer denial reasons — which also makes it easier to appeal. See How Do I… appeal a denial. |
| Providers & billing | Electronic prior auth and firm timelines should cut phone-and-fax delays, but require adopting new electronic workflows. |
| Brokers & advisors | A genuine plan-quality differentiator clients ask about; know how plans handle authorizations. |
| Case managers & navigators | Shorter decision windows help move care forward; published metrics help identify problem patterns. |
| Health-plan operations | Substantial build: decision-timeline compliance, denial-reason transparency, public reporting, and new interoperability APIs. |
Tighter Medicare marketing rules
In response to complaints about aggressive and misleading Medicare Advantage and Part D advertising, CMS strengthened its marketing rules. Changes include stricter oversight of third-party marketing organizations, a required standardized disclaimer stating that a caller doesn't offer every plan in the area, limits on misleading advertisements, and requirements around recording sales calls and documenting a beneficiary's permission to be contacted.
| Audience | Impact |
|---|---|
| Members & caregivers | Fewer misleading ads and high-pressure tactics; clearer disclosure of what an agent does and doesn't offer. For unbiased help, use SHIP counseling. |
| Brokers & advisors | The most affected group: stricter compliance around Scope of Appointment, disclaimers, call recording, and permitted contact — with real penalties. See For Brokers, Agents & Advisors. |
| Case managers & navigators | Helps protect vulnerable clients from bad sales practices; reinforces steering-free referrals. |
| Health-plan operations | Oversight of downstream marketing partners, complaint tracking, and marketing-material review obligations. |
Marketplace subsidy levels (watch this one)
Legislation temporarily increased the premium tax credits that lower the cost of Marketplace (ACA) coverage, making more people eligible for larger subsidies. Because these enhancements were enacted for a limited period, they are subject to expiring or being extended by further legislation. This is a good example of a change whose current status you should always verify.
| Audience | Impact |
|---|---|
| Members & caregivers | Your monthly premium can change substantially depending on whether enhanced subsidies apply — recheck each open enrollment (see Enrollment & Deadlines). |
| Brokers & advisors | Subsidy levels shift affordability and plan choice; re-run each client's eligibility annually. |
| Case managers & navigators | Affects who can afford Marketplace coverage — especially important for people transitioning off Medicaid. |
| Health-plan operations | Enrollment volume and risk-pool composition can shift with subsidy changes. |
How to track changes yourself
- Federal Register — the official record of proposed and final federal rules, with public comment periods.
- CMS Newsroom — fact sheets and announcements written for a general audience.
- Medicare.gov and Medicaid.gov — current, member-facing program rules and numbers.
- Your state Medicaid agency — state-level changes and Medicaid renewal information.
- Your own plan's Annual Notice of Change (ANOC) — every Medicare Advantage and Part D plan must send members a yearly summary of what's changing.